The street thinks DSP is a bunch of suckers. Vant drugs are crap. And wholly owned subsidiary means Sunovion becomes red headed step child. Lights out for Sunovion passed Latuda is what Nomura-San hinted too. New DSP/Vant company can sell APL and 856.
A skeleton crew is needed until we replace over a billon in revenue. Going into an Oncology space that has Genentech, BMS, Celgene, to name a few with a COPD & CNS Sales force? I guess having products that are in phase 1 gives you time to prepare for a sales force flip into that space??? Not sure.
Here is a link from the corporate homepage that will tell you all you want to know. Sumitomo Dainippon Pharma Co., Ltd. Memorandum of Understanding for Strategic<br>Alliance with Roivant Sciences
The company is admitting the post Latuda period is looking very bleak. They need to do something to keep the doors open here in the US. This is a risky move, one that will make leadership heroes or has beens, depending on how many of these drugs actually come to fruition, and will they be another Latuda, or another Aptiom. Only time will tell, folks. And as Mae West said, "It's gonna be a bumpy ride!"
The Japanese are too polite to say it, but it is the closest we will hear them say or acknowledge they don't trust Sunovion R&D won't bungle and delay the '856 trials and screw up with getting another CRL again
